|
|
Volumn 91, Issue 2, 1999, Pages 110-112
|
|
Using HER2 to choose chemotherapy in breast cancer: is it ready for the clinic?
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
DOXORUBICIN;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
ARTICLE;
BREAST TUMOR;
CHEMISTRY;
CLINICAL TRIAL;
FEMALE;
HUMAN;
RETROSPECTIVE STUDY;
SURVIVAL;
TREATMENT OUTCOME;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BREAST NEOPLASMS;
CLINICAL TRIALS;
DOXORUBICIN;
FEMALE;
HUMANS;
RECEPTOR, ERBB-2;
RETROSPECTIVE STUDIES;
SURVIVAL ANALYSIS;
TREATMENT OUTCOME;
|
|
EID: 0033585278
PISSN: 00278874
EISSN: None
Source Type: Journal
DOI: 10.1093/jnci/91.2.110 Document Type: Article |
|
Times cited : (14)
|
|
References (0)
|
